Gene therapy of experimental brain tumors using neural progenitor cells

Area of Science:

• Neuro-oncology
• Gene Therapy
• Stem Cell Biology

Background:

• Glioblastomas are aggressive primary brain tumors with poor prognoses.
• Current gene therapies face challenges with viral vector survival and tumor cell infiltration.
• Neural stem/progenitor cells offer a potential solution due to their migratory and engraftment capabilities.

Purpose of the Study:

• To evaluate the efficacy of neural progenitor cells engineered to express interleukin-4 (IL-4) for glioblastoma gene therapy.
• To assess the therapeutic potential of genetically modified neural stem cells in preclinical brain tumor models.

Main Methods:

• Gene transfer of interleukin-4 into mouse primary neural progenitor cells.
• Intracranial injection of engineered cells into established syngeneic glioblastomas in mice.
• Utilized immortalized rat neural progenitor cells for implantation into rat C6 glioblastomas.
• Magnetic resonance imaging (MRI) and cell tracking (5-bromodeoxyuridine) to monitor tumor response and cell survival.

Main Results:

• Engineered neural progenitor cells secreting IL-4 significantly improved survival in tumor-bearing mice.
• Tumor regression was observed, with large tumors progressively disappearing as documented by MRI.
• Labeled progenitor cells were detected in the brain for several weeks post-injection, indicating stable engraftment.
• Similar positive outcomes were achieved using both mouse and rat neural progenitor cells in respective glioblastoma models.

Conclusions:

• Neural stem cell-based gene therapy, utilizing IL-4-producing cells, represents a novel and effective strategy for treating glioblastomas.
• This approach overcomes limitations of traditional viral vectors by leveraging the natural properties of neural stem cells for targeted delivery and sustained therapeutic molecule production.
• The findings support the clinical translation of neural stem cell grafting for brain tumor gene therapy.